Taking stock of the drug industry, from the lab to the medicine chestFebruary 8, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Bayer STAT+ | Bayer, facing investor ire, appoints an outsider CEO The company named former Roche executive Bill Anderson as its new CEO on Wednesday, potentially ending a dramatic and difficult chapter. By Matthew Herper and Damian Garde STAT+ | CVS' Oak Street Health acquisition continues the industry's provider obsession CVS Health's $10.6 billion acquisition of Oak Street Health plants another flag in the latest era of health insurance industry consolidation. By Bob Herman and Tara Bannow Seizure drug offers hope of expanding the pool of donor hearts If supported by further trials, a new method could substantially increase the four-hour cap on storage time for a donor heart. By Elaine Chen Mike Reddy for STAT STAT+ | Verily, struggling to turn profits, taps a Starbucks veteran and 'Warcraft' master Stephen Gillett, the new CEO of Alphabet's Verily, now finds himself in charge of a high-profile effort to transform health care with tech. By Casey Ross Opinion: Pregnant people with substance use disorders need treatment, not criminalization People with active substance use disorders during and after pregnancy need support, not barriers to treatment or criminalization. By Nora D. Volkow More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments